NCT01799798View on ClinicalTrials.gov

Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

Denosumab

Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.

Trial Locations (1)

50924

University Cologne, Childrens Hospital, Cologne, Germany, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT01799798 - Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab | Biotech Hunter | Biotech Hunter